-38%

est. 2Y upside i

Healthcare

Rank

#2956

Sector

Healthcare Technology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Clover Health presents a moderate upside opportunity for a job seeker, with an expected return of 27.5% over a two-year horizon.

Last updated: March 10, 2026

Bull (25%)+100%

Clover Health achieves consistent GAAP profitability in 2026 and beyond, driven by strong Medicare Advantage membership growth (46%+ YoY) and increasing adoption of its Clover Assistant and Counterpart Health platforms, which also gain traction with third-party payers after becoming the first live on a CMS Aligned Network. This execution, combined with a 4-star payment year, pushes its valuation to a more respectable 1x-1.5x forward revenue, reaching $2.0B+ market cap.

Base (40%)+50%

Clover Health continues its strong membership growth and achieves GAAP profitability in 2026, but faces ongoing margin pressure from elevated medical costs and intense competition from large incumbents like Humana and United Healthcare. Its Clover Assistant platform shows moderate external adoption. The company's market cap grows to $1.5B, reflecting its growth but still discounted due to execution risks and competitive landscape.

Bear (35%)-50%

Clover Health struggles to sustain GAAP profitability due to higher-than-expected medical costs and increased competition, exacerbated by a potential 2027 Star Ratings downgrade. The expansion of Counterpart Health is slower than anticipated, and the Altman Z-score distress signals (0.49) materialize into further financial challenges, including potential cash runway issues. This leads to a significant decline in market confidence and a market cap of $0.5B, wiping out a substantial portion of common stock value.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

90%

Investors have funded $938M into the company. At the current $1.0B market cap, this represents 93.8% of the company's value, indicating that early investors may have significant liquidation preferences from prior funding rounds at higher valuations, potentially impacting common stock returns in a low-valuation exit.

Dilution Risk

moderate

While the company aims for GAAP profitability in 2026, it reported a net loss in Q4 2025 and 'less than 1 year of cash runway' was flagged as a risk, suggesting potential for future capital raises and dilution if profitability is delayed or insufficient.

Secondary Liquidity

active

Shares are actively traded on NASDAQ under the ticker CLOV.

Other — 79 roles

View all 79 open roles at Clover Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Clover Health's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large players like Humana and United Healthcare, how does Clover Health plan to differentiate and sustain its market share beyond its current growth trajectory?”

  • 2

    “With the goal of achieving GAAP profitability in 2026, what are the key operational levers the company will pull to manage medical costs and improve its Insurance Benefit Expense Ratio, especially considering the 90.9% reported in 2025?”

  • 3

    “Clover Health went public via SPAC at an implied $3.7B valuation, but its current market cap is around $1.0B. How does the company communicate the long-term equity value proposition to employees, especially considering the significant funding raised ($938M) relative to the current valuation?”

Community

Valuation Sentiment

Our model estimates -38% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.